BioWorld4 天
Cargo stops firi-cel phase II on safety, durability; stock sinks
In a devastating blow to the company and large B-cell lymphoma patients relapsed or refractory to CD19 CAR T-cell therapy, Cargo Therapeutics Inc. terminated the phase II study of its lead CD22 cell ...
FierceBiotech4 天
Cargo offloads CAR-T along with half of its workforce in wake of low efficacy, toxic side ...
The drug in question, called firicabtagene autoleucel or firi-cel, is an autologous CD22 CAR-T cell therapy that had been ...
来自MSN1 个月
Dual Targeted CAR-T Yields 99% Response Rate in Pediatric ALL
"Bicistronic CD19/CD22-targeted CAR T-cell therapy is a safe and effective regimen which achieved durable remission in children with relapsed or refractory B-ALL, including those with isolated and ...
BioPharma Dive4 天
Cargo to drop lead CAR-T therapy, lay off staff after study setback
Safety concerns and disappointing results led Cargo to stop testing the treatment, cut 50% of its workforce and evaluate strategic alternatives.
BioSpace4 天
Cargo Halts CAR T Trial, Lays Off 50% of Workforce in Pipeline Reset
CAR T–focused biotech Cargo Therapeutics surprised and disappointed analysts when it announced that it would discontinue a ...
precisionmedicineonline4 天
Cargo Therapeutics Nixes Phase II CAR T-Cell Study, Cuts Workforce by 50 Percent
The changes will extend the company's cash runway, enabling it to advance a tri-specific CAR T-cell candidate and its allogeneic cell therapy platform.